Many lines of clinical evidence support the potential role of aspirin in cancer prevention
[6]; however, its use in clinical practice is held back by the possible risk of side effects, mainly bleeding
[8]. Considering data from the last decade, the meta-analysis by Rothwell et al. has to be mentioned
[9]. It included eight randomized clinical trials for primary or secondary prevention of vascular disease. Participants were randomized to aspirin versus placebo, the aspirin dose covering a wide range (from 75 to 1200 mg per day). Data showed a death reduction from different cancers starting after the fifth year of follow-up. Within the second decade, specifically for CRC, a statistical significant death reduction reached 49%, maintaining a 40% reduction with longer follow-up. For CRC, aspirin, even at the lower dose of 75 mg/day used for cardiovascular disease prevention, reduced cancer mortality and cancer incidence
[10]. The incidence decreased by 24% (p = 0.02) for colon cancer, reaching a 55% reduction (p = 0.001) for proximal colon, but a not significant 10% reduction for rectal cancer was shown. The risk-reducing effect of aspirin on cancer is seen overall in the gastrointestinal tract. Further analyses of cancer events in randomized clinical trials with aspirin
[9][11][12][13] for cardiovascular disease prevention showed: (1) detectable benefits at daily doses as low as 75 mg; (2) an apparent chemopreventive effect of aspirin saturable at low doses (i.e., 10- to 20-fold higher doses were not more effective than lower doses); and (3) a chemoprevention apparent effect in men at high cardiovascular risk treated with a 75-mg of controlled-release aspirin.
Overall, pre and post intake showed a significant 30 to 40% mortality reduction. The finding was that long-term aspirin use before a diagnosis of nonmetastatic CRC may be associated with lower CRC-specific mortality after diagnosis, consistent with possible inhibition of micrometastases before diagnosis. Recently, Lau et al.
[17] showed that standard cardiovascular disease risk factors are associated with increased risk of future cancer in participants (free of cancer at baseline) of FHS (Framingham Heart Study) and PREVEND (Prevention of Renal and Vascular End-Stage Disease). These are prospective, longitudinal community-based observational cohort studies
[18][19][20]. These data suggest that the association between cardiovascular health and future cancer is attributable to shared risk factors
[17]. The study by Zhang et al.
[16] included a large population and a long follow-up, thus showing evidence that a clearer benefit is detected only after 10 years of aspirin use, and it persists despite continuing use or not. This 10-year latency before the benefit of aspirin-based chemoprevention was previously shown in several studies.
Mechanisms driving aspirin potential in CRC chemoprevention are still under debate and will be discussed below.
Clinical decision-making in this setting is guided by evaluating the risk of cardiovascular disease, CRC, and bleeding
[21]. The U.S. preventive services task force (USPSTF) recommends initiating low-dose (81mg/day) aspirin use for CRC primary prevention in adults aged 50–59 years or 60–69 years who have a 10% or greater 10-year cardiovascular disease risk, are not at increased risk of bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. In contrast, evidence is insufficient among those aged 50 years old and younger or 70 years and older. Based on new analyses of the evidence from primary cardiovascular disease prevention
[22] and the results of the ASPREE trial
[23], the USPSTF has changed the age ranges and grades of its recommendation on aspirin use (
https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/aspirin-use-to-prevent-cardiovascular-disease-preventive-medication#bootstrap-panel--4, accessed on 1 December 2021). The decision to initiate low-dose aspirin use for the primary prevention of cardiovascular disease in adults ages 40 to 59 years who have a 10% or greater 10-year cardiovascular disease risk should be an individual one. USPSTF recommends against initiating low-dose aspirin use for the primary prevention of cardiovascular events in adults age 60 years or older. However, persons who are not at increased risk of bleeding and are willing to take low-dose aspirin daily are more likely to benefit. The ASPREE trial put a substantial warning against using aspirin in elderly subjects
[23]. The trial enrolled 19,114 persons with a median age of 74 years. Follow-up was stopped at 4.7 years since aspirin use did not improve the primary endpoint, i.e., disability-free survival (death, dementia, or persistent physical disability), and a higher rate of hemorrhagic events was obverted (HR, 1.38; 95% CI, 1.18–1.62). In particular, the overall mortality was higher in the aspirin arm (HR, 1.14; 95% CI, 1.01–1.29) with a major contribution of cancer-related mortality (HR, 1.31; 95% CI, 1.10–1.56). The message was that in the elderly, the risk-benefit ratio of primary prevention with aspirin is not advisable. Notably, cancer prevention is not realistic in an older population since a long time is needed to obtain anticancer protection.
Nevertheless, dose and duration remain open issues.
Precision medicine by tailoring drug treatment to specific individuals or populations could help to improve efficacy while reducing side effects; however, selecting the appropriate target population requires information on genetic and other biomarkers, together with environment and lifestyle for each person. These detailed patient data will be integrated using structured ontological approaches, analytics, mathematics, and statistics which constitute the tools of quantitative systems pharmacology; this strategy can predict drug efficacy and safety on an individual basis. The selection of patients and the dose for aspirin treatment will be performed using machine learning algorithms based on demographic, clinical, genetic, and biochemical information, such as BMI, diabetes, previous cardiovascular diseases, smoking status, genetic variants, inflammatory status, microenvironment (including microbiota and DNA methylation status), and risk factors for susceptibility to bleeding.
3. Clinical Pharmacology of Aspirin and Non-Invasive Biomarkers for Drug Response Prediction and Monitoring
3.1. Mechanism of Action of Aspirin
Aspirin (i.e., acetylsalicylic acid, ASA) is an NSAID
[25]. At therapeutic doses, NSAIDs act by inhibiting prostanoid biosynthesis in different cell types, therefore producing anti-inflammatory, analgesic, and antipyretic effects associated with lower incidence of some side effects (mainly bleeding and hypertension)
[25]. The therapeutic actions are mediated primarily by inhibiting the COX activity of the inducible COX-2. Aspirin causes analgesic and anti-inflammatory effects when administered at 350–600 and 1200 mg, respectively
[26].
In contrast to other NSAIDs that rapidly or slowly reverse inhibitors of COX-isozymes, the binding of aspirin to the COX active site is followed by covalent modification of COX-1 and COX-2, i.e., the acetylation of a specific serine residue located at position 529 and 516, respectively
[25]. Thus, aspirin causes irreversible inhibition of the catalytic activity of COX-isozymes, which become unable to transform arachidonic acid (AA) to prostaglandin (PG)G2 and PGH2, the common substrate for many downstream isomerases and synthases, catalyzing its conversion to different prostanoids
[25].
3.2. Aspirin Affects Platelet COX-1 at Low-Doses
Aspirin has a short half-life (approximately 20 min); thus, the aspirin pharmacological effect duration depends on the rate of COX-2 protein synthesis. In a nucleated cell, COX-2 turnover is fast; thus, aspirin has to be administered every 4–6 h to obtain a persistent pharmacological effect. Once-daily aspirin administration at medium-high doses can produce only a transient inhibition of COX-2 activity due to rapid de novo protein synthesis. Several lines of evidence have shown that some NSAIDs, including aspirin, can inhibit the proliferation and induce apoptosis of colon cancer cells in vitro independently from their inhibitory effect on COX-2-dependent prostanoid biosynthesis
[26]. However, these off-target effects have been mainly detected in vitro at very high concentrations of aspirin, often in the millimolar range that are not reached in vivo, in the systemic circulation, even when aspirin is administered at high anti-inflammatory doses.
In contrast, the irreversible inactivation of COX-1 in platelets (which do not express COX-2) by aspirin is long-lasting due to a low rate of de novo protein synthesis in the anucleated cell. Thus, low doses (75–100 mg) of aspirin given once a day are appropriate to cause a maximal inhibitory effect of platelet COX-1 activity (almost complete), which persists throughout the interval between doses
[27]. Another interesting aspect of aspirin pharmacodynamics is that the drug has an early inhibitory action on platelet COX-1 in the presystemic circulation before first-pass partial deacetylation by the liver
[28]. The peculiar pharmacodynamics of low-dose aspirin explains its improved gastrointestinal safety versus high-dose aspirin or non-aspirin NSAIDs
[29].
Within the limitations of post hoc analyses of cancer events that were not pre-specified endpoints, the results of the Thrombosis Prevention Trial are of interest to make a mechanistic interpretation since the anticancer effect of aspirin was apparent in men at high cardiovascular risk treated with a 75-mg controlled-release aspirin formulation associated with very low concentrations (approx. 0.29 μM) measured in the systemic circulation
[30]. This aspirin formulation was developed to maximize cumulative inhibition of platelet COX-1 in the pre-hepatic circulation and minimize inhibition of COX-2 in the systemic compartment
[31]. Thus, the drug acts by inhibiting selectively platelet function with a limited systemic effect. Moreover, reduced risk of CRC (a pre-specified secondary endpoint) was detected in the long-term observational follow-up of the Women’s Health Study where aspirin was administered in alternate-day 100-mg aspirin versus placebo
[32]. These findings suggest that the chemopreventive effect of aspirin recapitulates its antiplatelet effect, i.e., a long-lasting duration
[27] and, most importantly, its saturability at low doses
[33].
Platelets are activated in response to environmental factors, atherosclerotic plaque rupture or fissuring, and intestinal mucosa damage. Activated platelets release a vast repertoire of mediators that may evoke numerous signaling pathways associated with a phenotypic switch of the cellular compartment of the stromal environment
[34]. These events alter epithelial and stromal cell interactions and create a tissue microenvironment that promotes intestinal neoplasia. A key event is represented by enhanced biosynthesis of prostaglandin (PG)E2 in the intestinal mucosa, which occurs in the early stages of tumor development through cyclooxygenase (COX)-1 activity, in association with the suppression of the prostaglandin-degrading enzyme 15-prostaglandin dehydrogenase (15-PGDH)
[6]. Later, COX-2 is induced and further increases PGE2 production, thus promoting colorectal adenoma
[35] and its progression to adenocarcinoma
[36].
3.3. Low-Dose Aspirin Causes a Direct Inhibitory Effect on COX-1 Expressed in Colorectal Mucosa
The development of a novel direct biomarker of drug action via the assessment of the acetylation of COX-1 at serine 529 has allowed showing that low-dose aspirin acetylates normal colorectal mucosal COX-1
[27], even if at a lower extent versus platelet COX-1
[37]. This effect of low-dose aspirin is associated with reduced biosynthesis of colorectal mucosal COX-1-dependent PGE2 and its capacity to induce the phosphorylation of ribosomal protein S6 (p-S6)
[37]; p-S6 regulates the size of some cell types but is also dispensable for the translational control of mRNAs.
The ratio of p-S6/S6 is associated with tumor progression. Thus, the antitumorigenic effect of low-dose aspirin can also involve the prevention of S6 phosphorylation via the inhibition of colorectal mucosal COX-1-dependent PGE2 generation.
Enhanced PGE2 production can also disrupt the normal apoptotic processes, allow the affected cells to accumulate genetic mutations, and ultimately lead to loss of proliferative control
[35][36].
Moreover, it may suppress immune functions and facilitate tumor immune escape.
Thus, low-dose aspirin can affect early events of intestinal tumorigenesis indirectly via the inhibition of platelet function and in part directly by affecting intestinal mucosa COX-1-dependent PGE2.
3.4. Low-Dose Aspirin Can Indirectly Prevent COX-2 Induction in Colorectal Mucosa
The induction of COX-2 in the colorectal mucosa is associated with the aberrant increase of PGE2 production, thus promoting the progression of colorectal adenoma to adenocarcinoma
[6]. The possible contribution of platelet activation on COX-2 induction first in the stromal compartment and then in the epithelial cells of the colorectum has been proposed
[6]. Low-dose aspirin can indirectly prevent COX-2 induction by constraining platelet function. Whether low-dose aspirin can also directly inhibit colorectal COX-2 activity and PGE2 biosynthesis remains to be demonstrated. It is still unknown whether higher doses of aspirin can translate into a more profound inhibitory effect COX-2, thus improving the anticancer effect. Mechanistic studies are ongoing in Patrignani’s laboratory to address these issues, using the recently developed aspirin biomarker, which assesses the extent of acetylated COX-2 at serine 516 in CRC tissues together with the assessment of prostanoid biosynthesis in the cancer biopsies of CRC patients treated with aspirin at low and medium doses
[38].
3.5. Assessment of Biomarkers to Develop a Precision Therapy of CRC with Aspirin
Platelets can uptake circulating proteins and RNAs/microRNAs, thus acquiring a different intracellular molecular repertoire specific to the individual clinical condition. The analysis of platelet content (and of platelet-derived microvesicles), as a whole of transcript (transcriptomics) or proteins (proteomics), has the promise of being a novel tool for diagnosis and prognosis of several diseases, including cancer
[39].
The analysis of systemic prostanoid biosynthesis (by measuring the urinary levels of prostanoid enzymatic metabolites) in patients at baseline or after aspirin treatment provides important information about the impact of aspirin on platelet activation, vascular and inflammatory state
[27][37][40].
Plasma markers, such as soluble tumor necrosis factor receptor-2, as well as tumor expression levels of genes involved in prostanoid biosynthesis or signaling pathways activated by the aberrant expression of COX-2, such as phosphatidylinositol 3-kinase
[41][42] have been suggested to identify those subjects who will respond to the antineoplastic effect of aspirin. Most of these studies suffer from the limitation of investigating large cohorts of nonrandomized participants who provided data on aspirin use in a questionnaire. Thus, these findings should be confirmed by large randomized clinical trials.
A systems biology approach to the analysis of heterogeneous datasets (genomics, epigenomics, proteomics, lipidomics, and clinical) would allow dynamic systems modeling of candidate pathways involved in the antineoplastic effect of aspirin. This strategy would also allow identifying susceptibility profiles for CRC and their use to develop new biomarkers to predict its occurrence and recurrence.
4. Conclusions
The leading international guidelines suggest discussing with Lynch syndrome carriers the possibility of using low-dose aspirin for CRC prevention. Researchers aim systematically promote this intervention with all Lynch syndrome carriers.In the decision process to aspirin use for CRC prevention in LS carriers, several issues have to be considered to balance pros and cons. The main point to consider are: (a) Age: older age is a contra since toxicity is increased and cancer prevention benefit requires years to be effective; (b) Higher risk genotypes (MLH1, MSH2, MSH6) could benefit more from a preventive intervention than PMS2; genotype may also influence the starting age: for MLH1 and MSH2 carriers the starting age could be 25 years old since their cumulative risk to develop cancer reaches 10% at 35 years, whereas MSH6 carriers could start aspirin later, approximately at 35/40 years old, since their cancer risk reaches 10% at 60 years old, and even later, if any PMS2 carriers; (c) For fertile women, the therapeutic advice has to be decided accordingly with their familial reproductive plan; (d) Helicobacter pylori should be tested and, if positive, eradicated before starting aspirin treatment; (e) a concomitant cardiovascular disease increased risk, a previous diagnosis of CRC with a preserved portion of colon-rectum, or any other syndromic cancer with no sign of recurrence and an overall good prognosis are in favor of aspirin use; (f) BMI is controversial since in the CAPP2 study higher BMI was associated with an increased aspirin benefit, whereas other data suggest that aspirin may have a reduced activity in overweight subjects.
Researchers would like to propose a spontaneous program among the AIFET centers, discussing with Lynch Syndrome carriers the possibility of taking aspirin for CRC prevention and, after acceptance, monitoring for treatment adherence and side effects. Researchers' aim is also to seek predictive surrogate biomarkers and to monitor treatment efficacy.